Yao H - Search Results

1

The synthesis and evaluation of novel ALK inhibitors containing the sulfoxide structure.

Yao H, Ren Y, Wu F, Liu J, Cao L, Yan M, Li X. Yao H, et al. RSC Adv. 2024 May 31;14(25):17557-17570. doi: 10.1039/d4ra01556h. eCollection 2024 May 28. RSC Adv. 2024. PMID: 38828277 Free PMC article.

2

Synthesis and evaluation of novel 2,4-diaminopyrimidines bearing a sulfoxide moiety as anaplastic lymphoma kinase (ALK) inhibition agents.

Wu F, Yao H, Li W, Zhang N, Fan Y, Chan ASC, Li X, An B. Wu F, et al. Among authors: yao h. Bioorg Med Chem Lett. 2021 Sep 15;48:128253. doi: 10.1016/j.bmcl.2021.128253. Epub 2021 Jul 8. Bioorg Med Chem Lett. 2021. PMID: 34245852

3

Novel third-generation pyrimidines-based EGFR tyrosine kinase inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer.

An B, Liu J, Fan Y, Nie W, Yang C, Yao H, Li W, Zhang Y, Li X, Tian G. An B, et al. Among authors: yao h. Bioorg Chem. 2022 May;122:105743. doi: 10.1016/j.bioorg.2022.105743. Epub 2022 Mar 16. Bioorg Chem. 2022. PMID: 35313239

4

Synthesis and evaluation of new pirfenidone derivatives as anti-fibrosis agents.

Gu C, Li W, Ju Q, Yao H, Yang L, An B, Hu W, Li X. Gu C, et al. Among authors: yao h. RSC Adv. 2022 May 13;12(23):14492-14501. doi: 10.1039/d2ra00990k. eCollection 2022 May 12. RSC Adv. 2022. PMID: 35702193 Free PMC article.

5

Design, Synthesis, and Evaluation of New Mesenchymal-Epithelial Transition Factor (c-Met) Kinase Inhibitors with Dual Chiral Centers.

Yao H, Ren Y, Yan J, Liu J, Hu J, Yan M, Li X. Yao H, et al. Molecules. 2022 Aug 23;27(17):5359. doi: 10.3390/molecules27175359. Molecules. 2022. PMID: 36080127 Free PMC article.

6

Discovery of a potent EGFR and ALK dual mutation inhibitor containing N-(3-((4-((2-(cyclopropylsulfinyl)phenyl)amino)pyrimidin-2-yl)amino) phenyl)acrylamide scaffold.

Li W, Yao H, Gu C, Ren Y, Liu J, An B, Hu W, Li X, Chan ASC. Li W, et al. Among authors: yao h. Bioorg Chem. 2022 Dec;129:106188. doi: 10.1016/j.bioorg.2022.106188. Epub 2022 Oct 5. Bioorg Chem. 2022. PMID: 36220003

7

Novel Dual-Target Kinase Inhibitors of EGFR and ALK Were Designed, Synthesized, and Induced Cell Apoptosis in Non-Small Cell Lung Cancer.

Fan Y, Li W, Nie W, Yao H, Ren Y, Wang M, Nie H, Gu C, Liu J, An B. Fan Y, et al. Among authors: yao h. Molecules. 2023 Feb 21;28(5):2006. doi: 10.3390/molecules28052006. Molecules. 2023. PMID: 36903251 Free PMC article.

8

Synthesis and evaluation of sulfonamide derivatives targeting EGFR^790M/L858R mutations and ALK rearrangement as anticancer agents.

Cao L, Yao H, Yu L, Ren Y, Liu J, Li X, Jia X. Cao L, et al. Among authors: yao h. Bioorg Med Chem. 2023 May 1;85:117241. doi: 10.1016/j.bmc.2023.117241. Epub 2023 Mar 17. Bioorg Med Chem. 2023. PMID: 37087886

9

Discovery of potent and effective inhibitors containing sulfoxide structures targeting EML4-ALK rearrangement and EGFR mutant non-small cell lung cancer.

An B, Fan Y, Li W, Nie W, Nie H, Wang M, Feng J, Yao H, Zhang Y, Li X, Tian G. An B, et al. Among authors: yao h. Bioorg Chem. 2023 Sep;138:106653. doi: 10.1016/j.bioorg.2023.106653. Epub 2023 Jun 7. Bioorg Chem. 2023. PMID: 37302317

10

A novel c-Met/TRK inhibitor 1D228 efficiently inhibits tumor growth by targeting angiogenesis and tumor cell proliferation.

An B, Nie W, Hu J, Fan Y, Nie H, Wang M, Zhao Y, Yao H, Ren Y, Zhang C, Wei M, Li W, Liu J, Yang C, Zhang Y, Li X, Tian G. An B, et al. Among authors: yao h. Cell Death Dis. 2023 Nov 9;14(11):728. doi: 10.1038/s41419-023-06246-5. Cell Death Dis. 2023. PMID: 37945598 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

8,192 results

Search Page

Filters